Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | EIF4E | P06730 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | TOP1 | P11387 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | ATG7 | O95352 | 13/20 | 0.55 |
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572340 | 1.00 | LMNA (0.69) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL9780396 | 0.90 | ATG7 (0.56) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL25520855 | 0.85 | LMNA (0.73) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL12151510 | 0.85 | LMNA (0.73) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL11805366 | 0.83 | LMNA (0.70) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL15046105 | 0.83 | LMNA (0.70) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL6913914 | 0.83 | LMNA (0.70) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| SCHEMBL9780402 | 0.83 | ATG7 (0.58) | ATG7CA1CA2CA4CA9 | |
| SCHEMBL6554027 | 0.82 | LMNA (0.73) | LMNASMN1; SMN2ALDH1A1GLAEIF4E | |
| Ribavirin Monophosphate SCHEMBL1508870 | 0.82 | LMNA (0.69) | LMNASMN1; SMN2ALDH1A1GLAEIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353660-A1 | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs | OCTAGON THERAPEUTICS INC. (US) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353660-A1 | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs | IMPDH1, IMPDH2, PNP | LMNA 1199/4885SMN1; SMN2 4411/4885ALDH1A1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.